Advertisement
Advertisement
URGN
UroGen Pharma Ltd. Ordinary Shares
43.49
USDSponsored
+1.75
+4.19%
Sep 16, 15:59 UTC -4
Closed
After-Market
44.25
+0.76
+1.76%
URGN Earnings Reports
Positive Surprise Ratio
URGN beat 18 of 37 last estimates.
49%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$92.39M
/$0.12
Implied change from Q2 26 (Revenue/ EPS)
+27.52%
/-142.86%
Implied change from Q3 25 (Revenue/ EPS)
+236.20%
/-117.39%
UroGen Pharma Ltd. Ordinary Shares earnings per share and revenue
On Aug 05, 2026, URGN reported earnings of -0.28 USD per share (EPS) for Q2 26, beating the estimate of -0.29 USD, resulting in a 4.40% surprise. Revenue reached 72.46 million, compared to an expected 64.80 million, with a 11.82% difference. The market reacted with a +16.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of 0.12 USD, with revenue projected to reach 92.39 million USD, implying an decrease of -142.86% EPS, and increase of 27.52% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were UroGen Pharma Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, UroGen Pharma Ltd. Ordinary Shares reported EPS of -$0.28, beating estimates by 4.4%, and revenue of $72.46M, 11.82% above expectations.
How did the market react to UroGen Pharma Ltd. Ordinary Shares's Q2 2026 earnings?
The stock price moved up 16.31%, changed from $39.92 before the earnings release to $46.43 the day after.
When is UroGen Pharma Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for UroGen Pharma Ltd. Ordinary Shares's next earnings report?
Based on --
analysts, UroGen Pharma Ltd. Ordinary Shares is expected to report EPS of $0.12 and revenue of $92.39M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.